Review article · 2025 · Open access
Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation
Drug Development Research, 86(8), e70192 · Published 1 December 2025 · DOI 10.1002/ddr.70192
In brief
“Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation” is a 2025 review article by Mohamed S. Nafie and 6 co-authors, published in Drug Development Research. OpenAlex counts 10 citations as of 19 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Drug Development Research.
- Citations
- 10
- Most cited in
- 2026 (10)
- Field-weighted impact
- 0.71
- References
- 166
- Authors
- 7
Abstract
Proteolysis-targeting chimeras (PROTACs)-mediated protein degradation has been recently developed as a game-changing approach in oncology drug development. It represents a paradigm shift from traditional enzyme inhibition to selective protein degradation. PROTACs are different from regular small-molecule inhibitors because they are heterobifunctional compounds that use the ubiquitin-proteasome system to breakdown disease-causing oncogenic proteins. This review discusses the next generation of PROTAC platforms that innovate beyond traditional designs, such as dual-targeting PROTACS that present a novel mode of action, transcription factor-targeting PROTACs (TF-PROTACs), phosphorylation-dependent PROTACs (PhosphoTACs), and phosphorylation binding chimeras (PhosTACs). In kinase degradation, PROTACs have shown promise in addressing resistance mechanisms and carcinogenic drivers. Despite these advancements, issues with clinical pharmacokinetics, E3 ligase tissue selectivity, and subcellular localization persist. Additionally, the development of bio-responsive and spatially controlled PROTAC systems, such as photocaged and folate-caged PROTACs, was fully discussed, which achieves maximal precision in tumor selectivity. Furthermore, ARV-110 and ARV-471, as two representative PROTACs, have entered clinical trials, suggesting their potentially broader application. Accordingly, this review provides a critical overview of the design rationales, molecular mechanisms of action, therapeutic utilities, and synthetic issues associated with these innovative modalities, focusing on on their translational implication and pharmacokinetic limitations, as well as potential future clinical applications.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Nafie, M. S., Diab, M. K., Yassen, A. S. A., Elshamy, A. M., El Tohamy, M. R., Tawfik, H. O., & Fahmy, S. A. (2025). Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation. Drug Development Research, 86(8), e70192. https://doi.org/10.1002/ddr.70192
MLA 9
Nafie, Mohamed S., et al. “Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation.” Drug Development Research, vol. 86, no. 8, 2025, p. e70192. https://doi.org/10.1002/ddr.70192.
Chicago
Nafie, Mohamed S., Mohamed Khaled Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik, and Sherif Ashraf Fahmy. 2025. “Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation.” Drug Development Research 86 (8): e70192. https://doi.org/10.1002/ddr.70192.
Harvard
Nafie, M. S. et al. (2025) ‘Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation’, Drug Development Research, 86(8), p. e70192. doi:10.1002/ddr.70192.
IEEE
M. S. Nafie et al., “Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation,” Drug Development Research, vol. 86, no. 8, p. e70192, 2025, doi: 10.1002/ddr.70192.
BibTeX
@article{nafie2025next,
title = {{Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation}},
author = {Nafie, Mohamed S. and Diab, Mohamed Khaled and Yassen, Asmaa S. A. and Elshamy, Amany M. and El Tohamy, Mohamed R. and Tawfik, Haytham O. and Fahmy, Sherif Ashraf},
journal = {Drug Development Research},
year = {2025},
volume = {86},
number = {8},
pages = {e70192},
doi = {10.1002/ddr.70192},
url = {https://doi.org/10.1002/ddr.70192}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- PROTACs
- targeted protein degradation
- precision oncology
- tumor-selective drug delivery
- ARV-471
- resistance mechanisms
- pharmacokinetics
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Nafie, M. S., Diab, M. K., Yassen, A. S. A., Elshamy, A. M., El Tohamy, M. R., Tawfik, H. O., & Fahmy, S. A. (2025). Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation. Drug Development Research, 86(8), e70192. https://doi.org/10.1002/ddr.70192
How many times has this paper been cited?
10 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Drug Development Research: sign in and open the PDF from this page.
Who wrote this paper?
Mohamed S. Nafie, Mohamed Khaled Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik, Sherif Ashraf Fahmy.
What is the DOI of this paper?
10.1002/ddr.70192, permanently at https://doi.org/10.1002/ddr.70192. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.